Company intelligence / Profile preview
Suzhou Ruotai Pharmaceutical Technology
Suzhou, Jiangsu, Chinaroyaltechmed.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Suzhou Ruotai Pharmaceutical Technology has a diversified pipeline with at least 14 programs spanning oncology, infectious disease, hematology/immune disorders. The company is developing therapeutics using modalities such as oncolytic viruses, cell therapies, microbiota-based approaches, mRNA drugs and AAV gene therapies. At least one program has reached the clinical stage for advanced cervical carcinoma; others are in preclinical or early development.
- Therapeutic areas
- OncologyHematologyImmunologyInfectious Diseases
- Modalities
- MicrobiotaOncolytic virusCell therapymRNA-based drugsAAV based gene therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Suzhou Ruotai Pharmaceutical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Ruotai Pharmaceutical Technology.